Ledinbio – Leading the future of cataract treatment

Transforming how cataracts are diagnosed and reversed

We know cataracts develop when ageing or injury occurs and changes the tissue that makes up the eye’s lens. When we’re young, our lenses are like clear glass. When cataracts form, the proteins in the lens of your eye change shape and clump together. Because of this, the light doesn’t go straight through the lens. It bounces and scatters, which means your vision becomes like frosted bathroom glass; blurry, hazy and cloudy.

Ledinbio – The world’s first non-invasive cataract solution

Cataracts are diagnosed by examining the patient’s lens and comparing it to a standard lens. The LOCS III system is most commonly used and grades the cataract by position (nuclear, cortical or posterior subcapsular), with opacity (cloudiness) graded from 1-5. Ledinbio can monitor the changes in the lens by measuring the light emitted from the protein aggregates when excited with ultra-violet rays. This enables Ledinbio to diagnose cataracts.

Ledinbio can also treat cataracts by delivering light energy with specific wavelengths, which we believe cause chemical changes to the lens and proteins, allowing the proteins to return to their normal shape. This means that the protein in your eyes adjusts and it stops the scatter and reflection, thus allowing the light through the lens so you can see clearly again, without the need for surgery.

Ledinbio is the first non-surgical treatment for cataracts, which makes it much easier for people to access, as it will be provided by optometrists instead of in a hospital. It’s a fast procedure that you can access 90% quicker than NHS surgery, with up to ten people being able to receive the treatment in a day from just one device. It also benefits the opticians and ophthalmologists as it creates a whole new source of income. The cost of treatment is also significantly reduced for both the patient and healthcare systems.

Optometrists delivering cataract treatment

Optometrists and clinical assistants can deliver the treatment, which will be significantly cheaper than surgery, with the treatment costing £1K per eye. With no upfront cost to the Optometrist, we supply them with the Ledinbio device and only charge a small minimum monthly fee. We then share the patient payments. Optometrists will be able to deliver both the diagnosis and treatment in-store and we are already in discussion with UK retail opticians.

Ledinbio delivers disruptive change to a market suffering from backlog and lack of innovation.

Ledinbio will be easily accessible to everyone, including those with underlying health conditions who can’t currently receive surgery. Ledinbio will be more affordable, with the treatment costing only £1000 per eye instead of the £2500 per eye you would currently pay for private treatment. This reduces the cost enormously, not just for the patient, but the healthcare system. The result is that Ledinbio will offer a faster more easily accessed solution as opposed to waiting on the lengthy NHS waiting list and a more affordable option for those considering private surgery.

We are currently carrying out clinical trials, which are showing that visual acuity has been improved in moderate cataracts with patients reporting significant improvements in their quality of life. We are planning to launch Ledinbio by early 2025 and look forward to seeing the use of Ledinbio in optometrists all over the UK. If you’d like to keep in touch and receive updates you can follow us on our social media platforms, or contact us on +44 (0) 1506 429 274 or email us at info@edinbio.com.